Navigation Links
Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World

GLEN BURNIE, Md., May 3, 2011 /PRNewswire/ -- Answering the need for global, site-focused enrollment support, Clinical Site Services (CSS), a leader in the patient enrollment industry, announces the expansion of its services to include global enrollment planning and implementation on a local, site-centric level.

"The extension of our worldwide presence is an important step that will allow us to assist sponsors with their global patient enrollment needs," says Chris Trizna, President of Clinical Site Services. "To date, we have been quite successful in delivering patient enrollment solutions to investigative sites and sponsors in North America; this expansion means that sponsors no longer need to seek out different patient recruitment partners for North American and Rest-of-World needs."

The CSS London-based office, headed up by industry executive Richard Anderson, will tap into professionals who have more than 20 years of experience in the life science, healthcare and patient recruitment industries. They will be able to implement patient enrollment and retention campaigns which are solely based in global markets, or as an adjunct to North American endeavors.

As with all CSS North American campaigns, the global programs will offer customized clinical research support and expertise. Through Local Enrollment Specialists, regional experts who have detailed knowledge of each country's regulatory provisions, CSS will provide site assessments, chart reviews, ethics committee submissions, local patient enrollment expertise, planning and implementation in more than 40 countries.

"This is an exciting new initiative. For the first time a patient enrollment provider can support sites at local level in over 40 countries," stated Richard Anderson, CSS Director of Global Patient Enrollment. "The teams will be working with the sites to help optimize their patient enrollment programs, maximizing enrollment and ROI."

All international endeavors will be centrally managed by CSS's project team.

"It all comes down to enrollment. Generating interest is important, but it's what happens after that," shared Trizna. "Sites are the only ones who can enroll patients. Successful sites consistently meet their enrollment goals. We are poised to support them with enrollment planning and implementation."

About Clinical Site Services

Founded in 2005, Clinical Site Services (CSS) is a global enrollment performance company that increases enrollment and retention for pharma, CROs and investigative sites through a site-focused approach and adaptive enrollment process.

US Contact:
Jennifer Whitlock
VP/Director of Marketing
Clinical Site Services
P: 410-793-1067
F: 410-553-0087

UK Contact:
Richard Anderson
Director of Global Patient Enrollment
Clinical Site Services
P: +44 020 8347 9935

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Clinical Site Services
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Omnicare Clinical Research Acquired by Nautic Partners, LLC
3. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
4. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
5. Tissue Genesis Begins FDA-Approved Clinical Trial
6. ClearCanvas Releases First Commercial Version of Popular Clinical Radiology Workstation; PACS and RIS to Follow
7. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
8. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
9. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
10. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
11. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
Breaking Biology News(10 mins):